124 related articles for article (PubMed ID: 24529556)
21. Localized RNAi therapeutics of chemoresistant grade IV glioma using hyaluronan-grafted lipid-based nanoparticles.
Cohen ZR; Ramishetti S; Peshes-Yaloz N; Goldsmith M; Wohl A; Zibly Z; Peer D
ACS Nano; 2015 Feb; 9(2):1581-91. PubMed ID: 25558928
[TBL] [Abstract][Full Text] [Related]
22. The Internalization of Neurotensin by the Low-Affinity Neurotensin Receptors (NTSR2 and vNTSR2) Activates ERK 1/2 in Glioma Cells and Allows Neurotensin-Polyplex Transfection of tGAS1.
Ayala-Sarmiento AE; Martinez-Fong D; Segovia J
Cell Mol Neurobiol; 2015 Aug; 35(6):785-95. PubMed ID: 25772140
[TBL] [Abstract][Full Text] [Related]
23. Combination of a ptgs2 inhibitor and an epidermal growth factor receptor-signaling inhibitor prevents tumorigenesis of oligodendrocyte lineage-derived glioma-initiating cells.
Hide T; Takezaki T; Nakatani Y; Nakamura H; Kuratsu J; Kondo T
Stem Cells; 2011 Apr; 29(4):590-9. PubMed ID: 21360625
[TBL] [Abstract][Full Text] [Related]
24. Glioma gene therapy using induced pluripotent stem cell derived neural stem cells.
Lee EX; Lam DH; Wu C; Yang J; Tham CK; Ng WH; Wang S
Mol Pharm; 2011 Oct; 8(5):1515-24. PubMed ID: 21755959
[TBL] [Abstract][Full Text] [Related]
25. Human neural stem cells target experimental intracranial medulloblastoma and deliver a therapeutic gene leading to tumor regression.
Kim SK; Kim SU; Park IH; Bang JH; Aboody KS; Wang KC; Cho BK; Kim M; Menon LG; Black PM; Carroll RS
Clin Cancer Res; 2006 Sep; 12(18):5550-6. PubMed ID: 17000692
[TBL] [Abstract][Full Text] [Related]
26. Effect of human skin-derived stem cells on vessel architecture, tumor growth, and tumor invasion in brain tumor animal models.
Pisati F; Belicchi M; Acerbi F; Marchesi C; Giussani C; Gavina M; Javerzat S; Hagedorn M; Carrabba G; Lucini V; Gaini SM; Bresolin N; Bello L; Bikfalvi A; Torrente Y
Cancer Res; 2007 Apr; 67(7):3054-63. PubMed ID: 17409412
[TBL] [Abstract][Full Text] [Related]
27. [Progress in the study of brain tumor stem cells as treatment targets].
Hide T; Kuratsu J
Brain Nerve; 2009 Jul; 61(7):781-9. PubMed ID: 19618855
[TBL] [Abstract][Full Text] [Related]
28. Primary neural stem/progenitor cells expressing endostatin or cytochrome P450 for gene therapy of glioblastoma.
Lorico A; Mercapide J; Solodushko V; Alexeyev M; Fodstad O; Rappa G
Cancer Gene Ther; 2008 Sep; 15(9):605-15. PubMed ID: 18421309
[TBL] [Abstract][Full Text] [Related]
29. Tumoricidal stem cell therapy enables killing in novel hybrid models of heterogeneous glioblastoma.
Satterlee AB; Dunn DE; Lo DC; Khagi S; Hingtgen S
Neuro Oncol; 2019 Dec; 21(12):1552-1564. PubMed ID: 31420675
[TBL] [Abstract][Full Text] [Related]
30. Glycoprotein nonmetastatic melanoma protein B, a potential molecular therapeutic target in patients with glioblastoma multiforme.
Kuan CT; Wakiya K; Dowell JM; Herndon JE; Reardon DA; Graner MW; Riggins GJ; Wikstrand CJ; Bigner DD
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):1970-82. PubMed ID: 16609006
[TBL] [Abstract][Full Text] [Related]
31. Glial-specific retrovirally mediated gas1 gene expression induces glioma cell apoptosis and inhibits tumor growth in vivo.
Zamorano A; Mellström B; Vergara P; Naranjo JR; Segovia J
Neurobiol Dis; 2004 Apr; 15(3):483-91. PubMed ID: 15056455
[TBL] [Abstract][Full Text] [Related]
32. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: effects on gene expression and growth of glioma cells in vitro and in vivo.
Yin D; Ong JM; Hu J; Desmond JC; Kawamata N; Konda BM; Black KL; Koeffler HP
Clin Cancer Res; 2007 Feb; 13(3):1045-52. PubMed ID: 17289901
[TBL] [Abstract][Full Text] [Related]
33. Primary gene-engineered neural stem/progenitor cells demonstrate tumor-selective migration and antitumor effects in glioma.
Mercapide J; Rappa G; Anzanello F; King J; Fodstad O; Lorico A
Int J Cancer; 2010 Mar; 126(5):1206-15. PubMed ID: 19653275
[TBL] [Abstract][Full Text] [Related]
34. Potent tumor tropism of induced pluripotent stem cells and induced pluripotent stem cell-derived neural stem cells in the mouse intracerebral glioma model.
Yamazoe T; Koizumi S; Yamasaki T; Amano S; Tokuyama T; Namba H
Int J Oncol; 2015 Jan; 46(1):147-52. PubMed ID: 25310640
[TBL] [Abstract][Full Text] [Related]
35. Effect of the STAT3 inhibitor STX-0119 on the proliferation of cancer stem-like cells derived from recurrent glioblastoma.
Ashizawa T; Miyata H; Iizuka A; Komiyama M; Oshita C; Kume A; Nogami M; Yagoto M; Ito I; Oishi T; Watanabe R; Mitsuya K; Matsuno K; Furuya T; Okawara T; Otsuka M; Ogo N; Asai A; Nakasu Y; Yamaguchi K; Akiyama Y
Int J Oncol; 2013 Jul; 43(1):219-27. PubMed ID: 23612755
[TBL] [Abstract][Full Text] [Related]
36. Developing Bioinspired Three-Dimensional Models of Brain Cancer to Evaluate Tumor-Homing Neural Stem Cell Therapy.
Carey-Ewend AG; Hagler SB; Bomba HN; Goetz MJ; Bago JR; Hingtgen SD
Tissue Eng Part A; 2020 Oct; ():. PubMed ID: 33085922
[TBL] [Abstract][Full Text] [Related]
37. Gene delivery of apoptin-derived peptide using an adeno-associated virus vector inhibits glioma and prolongs animal survival.
Zhong X; Zhao H; Liang S; Zhou D; Zhang W; Yuan L
Biochem Biophys Res Commun; 2017 Jan; 482(3):506-513. PubMed ID: 28212737
[TBL] [Abstract][Full Text] [Related]
38. An RNAi screen identifies TRRAP as a regulator of brain tumor-initiating cell differentiation.
Wurdak H; Zhu S; Romero A; Lorger M; Watson J; Chiang CY; Zhang J; Natu VS; Lairson LL; Walker JR; Trussell CM; Harsh GR; Vogel H; Felding-Habermann B; Orth AP; Miraglia LJ; Rines DR; Skirboll SL; Schultz PG
Cell Stem Cell; 2010 Jan; 6(1):37-47. PubMed ID: 20085741
[TBL] [Abstract][Full Text] [Related]
39. Cell carriers to attack glioma.
Krebs S; Gottschalk S
Cytotherapy; 2014 Jul; 16(7):871-2. PubMed ID: 24910384
[No Abstract] [Full Text] [Related]
40. Systemic anticancer neural stem cells in combination with a cardiac glycoside for glioblastoma therapy.
Teng J; Hejazi S; Badr CE; Tannous BA
Stem Cells; 2014 Aug; 32(8):2021-32. PubMed ID: 24801379
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
